Abstract:Low-grade serous ovarian cancer (LGSOC) is a relatively rare pathological type of epithelial ovarian cancer, characterized by a younger age of onset, low sensitivity to chemotherapy, non-invasive biological behavior, slow progression, and longer progression- free survival and overall survival. Clinically, it is mainly diagnosed through routine pathological examination of postoperative specimens. Currently, surgery is the primary treatment for both first-line and recurrent LGSOC. Postoperatively, chemotherapy and endocrine therapy can be adopted based on the patient’s disease stage. At the same time, due to its insensitivity to chemotherapy, hormone and targeted therapies are expected to become the research and treatment directions for LGSOC.